Line H Tangerås1, Marie Austdal2, Ragnhild B Skråstad2, Kjell Å Salvesen2, Rigmor Austgulen2, Tone F Bathen2, Ann-Charlotte Iversen1. 1. From the Centre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine (L.H.T., R.A., A.-C.I.), Department of Circulation and Medical Imaging (M.A., T.F.B.), and Department of Laboratory Medicine Children's and Women's Health (R.B.S., K.Å.S.), Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (L.H.T., M.A.); and National Center for Fetal Medicine, Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (R.B.S., K.Å.S.). line.tangeras@ntnu.no ann-charlotte.iversen@ntnu.no. 2. From the Centre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine (L.H.T., R.A., A.-C.I.), Department of Circulation and Medical Imaging (M.A., T.F.B.), and Department of Laboratory Medicine Children's and Women's Health (R.B.S., K.Å.S.), Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (L.H.T., M.A.); and National Center for Fetal Medicine, Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (R.B.S., K.Å.S.).
Abstract
OBJECTIVE: Gestational hypertension and preeclampsia involve dysregulated maternal inflammatory responses to pregnancy, but whether such responses differ between the disorders has not been determined. We aimed to investigate disease-specific early pregnancy serum cytokine profiles of women subsequently developing gestational hypertension or preeclampsia for new insight into the underlying pathogeneses and differences between the disorders. APPROACH AND RESULTS: The study cohort consisted of 548 pregnant Norwegian women who were either multiparous with previous gestational hypertension or preeclampsia or were nulliparous. Maternal sera at gestational weeks 11(0)-13(6) were assayed for 27 cytokines, C-reactive protein, total cholesterol, high-density lipoprotein, triglyceride, creatinine, calcium, uric acid, and placental growth factor. Compared with normotensive women, women with both hypertensive conditions presented an atherogenic lipid profile at early gestation, but only those later developing gestational hypertension had significantly higher serum levels of interleukin (IL)-5 and IL-12. Comparing the 2 hypertensive pregnancy disorders, women subsequently developing gestational hypertension had higher serum levels of IL-1β, IL-5, IL-7, IL-8, IL-13, basic fibroblast growth factor, and vascular endothelial growth factor than the women subsequently developing preeclampsia. CONCLUSIONS: This study identifies early pregnancy differences in serum cytokine profiles for gestational hypertension and preeclampsia.
OBJECTIVE: Gestational hypertension and preeclampsia involve dysregulated maternal inflammatory responses to pregnancy, but whether such responses differ between the disorders has not been determined. We aimed to investigate disease-specific early pregnancy serum cytokine profiles of women subsequently developing gestational hypertension or preeclampsia for new insight into the underlying pathogeneses and differences between the disorders. APPROACH AND RESULTS: The study cohort consisted of 548 pregnant Norwegian women who were either multiparous with previous gestational hypertension or preeclampsia or were nulliparous. Maternal sera at gestational weeks 11(0)-13(6) were assayed for 27 cytokines, C-reactive protein, total cholesterol, high-density lipoprotein, triglyceride, creatinine, calcium, uric acid, and placental growth factor. Compared with normotensive women, women with both hypertensive conditions presented an atherogenic lipid profile at early gestation, but only those later developing gestational hypertension had significantly higher serum levels of interleukin (IL)-5 and IL-12. Comparing the 2 hypertensive pregnancy disorders, women subsequently developing gestational hypertension had higher serum levels of IL-1β, IL-5, IL-7, IL-8, IL-13, basic fibroblast growth factor, and vascular endothelial growth factor than the women subsequently developing preeclampsia. CONCLUSIONS: This study identifies early pregnancy differences in serum cytokine profiles for gestational hypertension and preeclampsia.
Authors: Shannon L Gillespie; Jeremy L Neal; Lisa M Christian; Laura A Szalacha; Donna O McCarthy; Pamela J Salsberry Journal: Nurs Res Date: 2017 Mar/Apr Impact factor: 2.381
Authors: Hajrunisa Cubro; Sonu Kashyap; Meryl C Nath; Allan W Ackerman; Vesna D Garovic Journal: Curr Hypertens Rep Date: 2018-04-30 Impact factor: 5.369
Authors: McKenzie K Wallace; Nitin Shivappa; Michael D Wirth; James R Hébert; Larraine Huston-Gordesky; Fernanda Alvarado; Sylvie Hauguel-de Mouzon; Patrick M Catalano Journal: Biol Res Nurs Date: 2021-01-29 Impact factor: 2.318
Authors: Camilo P Martínez-Reyes; Angélica Y Gómez-Arauz; Israel Torres-Castro; Aarón N Manjarrez-Reyna; León F Palomera; Alfonso Olivos-García; Edith Mendoza-Tenorio; Gabriela A Sánchez-Medina; Sergio Islas-Andrade; Guillermo Melendez-Mier; Galileo Escobedo Journal: J Diabetes Res Date: 2018-02-21 Impact factor: 4.011
Authors: Xiaoyuan Han; Mohammad S Ghaemi; Kazuo Ando; Laura S Peterson; Edward A Ganio; Amy S Tsai; Dyani K Gaudilliere; Ina A Stelzer; Jakob Einhaus; Basile Bertrand; Natalie Stanley; Anthony Culos; Athena Tanada; Julien Hedou; Eileen S Tsai; Ramin Fallahzadeh; Ronald J Wong; Amy E Judy; Virginia D Winn; Maurice L Druzin; Yair J Blumenfeld; Mark A Hlatky; Cecele C Quaintance; Ronald S Gibbs; Brendan Carvalho; Gary M Shaw; David K Stevenson; Martin S Angst; Nima Aghaeepour; Brice Gaudilliere Journal: Front Immunol Date: 2019-06-11 Impact factor: 7.561
Authors: Minxue Shen; Graeme N Smith; Marc Rodger; Ruth Rennicks White; Mark C Walker; Shi Wu Wen Journal: PLoS One Date: 2017-04-24 Impact factor: 3.240